Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PharmAsia News’ India Pharma Roundup: Biological E., Suven Life Sciences, Strides Arcolab, Dabur, Glenmark

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Biological E., which has a clinical trial network of 13,000 doctors and hospitals across India, signed an option and license agreement with U.S.-based Heparinex and Choncept to work on development of new methods to make anti-coagulant chondroitin derived from fermentation of recombinant bacteria to replace chondroitin sourced from beef and other animal by-products
Advertisement

Related Content

PharmAsia News India Pharma Roundup: Glenmark, FMRAI, Synchron/Parexel, Suven Life Sciences, Merck/Ranbaxy/Teva/Credit Suisse
PharmAsia News India Pharma Roundup: Glenmark, FMRAI, Synchron/Parexel, Suven Life Sciences, Merck/Ranbaxy/Teva/Credit Suisse
Contaminant Discovered In Chinese-Produced Heparin API
Contaminant Discovered In Chinese-Produced Heparin API
India's Nicholas Piramal Signs Second Potential $100 Million R&D Deal with Lilly
Advertisement
UsernamePublicRestriction

Register

SC067899

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel